UNITED THERAP Company Profile
✉ Email this page to a colleague
What is the competitive landscape for UNITED THERAP, and what generic alternatives to UNITED THERAP drugs are available?
UNITED THERAP has five approved drugs.
There are twenty-nine US patents protecting UNITED THERAP drugs. There is one tentative approval on UNITED THERAP drugs.
There are two hundred and eight patent family members on UNITED THERAP drugs in twenty-two countries.
Summary for UNITED THERAP
| International Patents: | 208 |
| US Patents: | 29 |
| Tradenames: | 4 |
| Ingredients: | 2 |
| NDAs: | 5 |
| Patent Litigation for UNITED THERAP: | See patent lawsuits for UNITED THERAP |
| PTAB Cases with UNITED THERAP as patent owner: | See PTAB cases with UNITED THERAP as patent owner |
Drugs and US Patents for UNITED THERAP
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United Therap | TYVASO DPI | treprostinil | POWDER;INHALATION | 214324-003 | May 23, 2022 | RX | Yes | No | 10,716,793 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| United Therap | TYVASO DPI | treprostinil | POWDER;INHALATION | 214324-004 | May 23, 2022 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
| United Therap | REMODULIN | treprostinil | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 021272-007 | Sep 28, 2023 | RX | Yes | Yes | 11,723,887 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| United Therap | ORENITRAM | treprostinil diolamine | TABLET, EXTENDED RELEASE;ORAL | 203496-004 | Dec 20, 2013 | RX | Yes | No | 9,593,066 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for UNITED THERAP
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| United Therap | REMODULIN | treprostinil | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 021272-003 | May 21, 2002 | 9,713,599 | ⤷ Subscribe |
| United Therap | ORENITRAM | treprostinil diolamine | TABLET, EXTENDED RELEASE;ORAL | 203496-002 | Dec 20, 2013 | 7,544,713 | ⤷ Subscribe |
| United Therap | ORENITRAM | treprostinil diolamine | TABLET, EXTENDED RELEASE;ORAL | 203496-005 | Oct 7, 2016 | 6,765,117 | ⤷ Subscribe |
| United Therap | REMODULIN | treprostinil | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 021272-003 | May 21, 2002 | 9,199,908 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for UNITED THERAP drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 1 mg/mL, 2.5 mg/mL, and 5 mg/mL, 20 mL vial | ➤ Subscribe | 2012-12-07 |
| ➤ Subscribe | Extended-release Tablets | 2.5 mg | ➤ Subscribe | 2015-12-24 |
| ➤ Subscribe | Injection | 10 mg/mL, 20 mL vial | ➤ Subscribe | 2011-12-02 |
| ➤ Subscribe | Inhalation Solution | 0.6 mg/mL, 2.9 mL ampules | ➤ Subscribe | 2015-04-13 |
| ➤ Subscribe | Extended-release Tablets | 0.25 mg and 1 mg | ➤ Subscribe | 2016-05-19 |
International Patents for UNITED THERAP Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 5649645 | ⤷ Subscribe |
| Australia | 2022235510 | ⤷ Subscribe |
| China | 1917866 | ⤷ Subscribe |
| China | 104721825 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
